Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed by U.S. President Donald Trump could affect its business.

Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its ...